Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
← Cardiology indexChapter sections
OverviewAetiologyPathophysiologyClinical features and red flagsInvestigationsDifferential diagnosisManagementComplicationsMonitoring and follow-upSpecial situationsCommon pitfallsQuestionsSources
Full textbook13 sectionsOpen only what you need
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.

Deep vein thrombosis

Cardiology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Time-critical presentation

DVT symptoms plus new breathlessness, chest pain, haemoptysis, syncope or haemodynamic compromise may indicate pulmonary embolism: activate the PE/emergency pathway rather than completing an isolated DVT work-up.

Overview

Apply the NICE two-level Wells pathway, avoid unsafe diagnostic delay and choose initial anticoagulation with UK-specific modifiers.

DVT usually presents with unilateral swelling, pain or tenderness, but examination is neither sensitive nor specific. Cellulitis, ruptured Baker cyst, muscle injury, superficial venous thrombosis, lymphoedema and chronic venous disease are common mimics.

NICE deliberately couples time-limited testing with interim treatment. Before interim anticoagulation, take baseline FBC, renal and hepatic function, PT and APTT, but do not wait for results unless there is a clinical reason to withhold treatment; review results within 24 hours.

Duration depends on recurrence and bleeding risk. A major transient provoking factor supports stopping after 3 months when the course was uncomplicated; unprovoked DVT often favours extended treatment after shared review.

Key points

  • Use the 2-level DVT Wells score: 2 points or more means DVT likely; 1 point or less means DVT unlikely.
  • Likely DVT: obtain proximal leg-vein ultrasound within 4 hours if possible; if delayed, give interim therapeutic anticoagulation and scan within 24 hours.
  • Unlikely DVT: obtain D-dimer within 4 hours; if delayed, give interim therapeutic anticoagulation while awaiting the result.
  • A positive D-dimer is not diagnostic; it triggers ultrasound. Consider an age-adjusted threshold for people over 50.
  • If initial proximal ultrasound is negative but D-dimer positive, repeat proximal ultrasound in 6–8 days.
  • Confirmed proximal DVT usually needs at least 3 months of anticoagulation; review provoked versus unprovoked risk, bleeding and recurrence at 3 months.
  • NICE generally offers apixaban or rivaroxaban first, but active cancer, triple-positive antiphospholipid syndrome, pregnancy, extremes of weight and renal/hepatic impairment alter choice.
  • Do not order thrombophilia testing while continuing anticoagulation or after a clearly provoked event unless a specific NICE indication will change management.

Aetiology

01

Venous stasis

Major surgery, trauma, hospitalisation, paralysis or prolonged immobility reduces calf-pump flow. Blood pooling in deep venous valve pockets favours local coagulation and thrombus propagation.

02

Endothelial injury

Surgery, fracture, inflammation or an indwelling venous catheter can disrupt or activate the endothelium. The injured surface supports platelet adhesion and coagulation.

03

Acquired hypercoagulability

Active cancer, pregnancy, the postpartum period and oestrogen exposure shift haemostasis towards thrombosis. Persistent inflammatory illness may add further risk, especially alongside immobility.

04

Persistent or inherited susceptibility

Previous unprovoked venous thromboembolism, antiphospholipid syndrome or selected inherited thrombophilias increase recurrence tendency. Testing is useful only when its result would change management.

Pathophysiology

  1. 1
    Virchow factors converge

    Stasis, endothelial activation and hypercoagulability act alone or together. Their balance explains why a transient event may provoke thrombosis in one person but not another.

  2. 2
    Deep venous thrombus forms

    Thrombin generation deposits fibrin and traps red cells, often near venous valve pockets. The clot may extend from calf veins into proximal femoral or iliac segments.

  3. 3
    Obstruction causes limb symptoms

    Venous outflow obstruction and local inflammation raise distal hydrostatic pressure. Fluid enters the interstitium, producing unilateral swelling, pain, tenderness and collateral superficial vein distension.

  4. 4
    Embolisation or organisation follows

    Part of the thrombus may detach and travel to pulmonary arteries. Residual clot can instead organise and recanalise, leaving damaged valves and chronic venous hypertension.

Clinical features and red flags

Typical lower-limb DVT

Unilateral calf or whole-leg swelling, deep venous tenderness, pitting oedema, increased circumference and collateral superficial veins.

Proximal/iliofemoral DVT

Whole-leg swelling, marked pain, groin/buttock symptoms or venous distension; carries greater embolic and post-thrombotic burden.

PhlegmasiaRed flag

Massive painful swelling, cyanosis, sensory/motor change or threatened perfusion from extensive venous occlusion requires emergency vascular/haematology assessment.

Pulmonary embolism cluesRed flag

Dyspnoea, pleuritic pain, tachycardia, haemoptysis, syncope, hypoxia or shock require immediate PE assessment.

Provoking factors

Recent surgery/trauma, significant immobility, pregnancy/postpartum, oestrogen, active cancer or an indwelling line affect probability and duration decisions.

Mimics

Cellulitis, haematoma, ruptured popliteal cyst, muscle tear, superficial thrombosis and unilateral lymphoedema can reproduce pain and swelling.

Investigations

  1. 01
    Two-level DVT Wells scoreFirst step
    Why
    Set the NICE diagnostic pathway before testing.
    Interpretation and limitations
    At least 2 points: DVT likely. 1 point or less: DVT unlikely. Record each component, including minus 2 when an alternative diagnosis is at least as likely.
  2. 02
    Quantitative D-dimer
    Why
    Rule out DVT in an appropriate low-probability pathway and determine repeat imaging after a negative scan.
    Interpretation and limitations
    A negative result in DVT-unlikely excludes DVT; a positive result needs ultrasound. Consider age-adjustment over age 50 according to assay/pathway.
  3. 03
    Proximal leg-vein compression ultrasound
    Why
    Confirm or exclude proximal DVT.
    Interpretation and limitations
    Non-compressibility confirms thrombosis. Negative scan plus positive D-dimer requires repeat proximal ultrasound in 6–8 days.
  4. 04
    FBC, U&E/eGFR, LFTs, PT and APTT
    Why
    Choose and safely dose anticoagulation and establish bleeding/organ-function baselines.
    Interpretation and limitations
    Take before interim therapy if possible but do not await results routinely; review within 24 hours and adjust/stop if necessary.
  5. 05

Differential diagnosis

01

Cellulitis

Skin infection causes warmth, erythema, tenderness and sometimes fever or a portal of entry. DVT more often produces deep venous tenderness and swelling without a dominant cutaneous focus.

02

Ruptured popliteal cyst

A Baker cyst can release fluid into the calf, causing acute pain and swelling. Knee symptoms or posterior cystic fluid on imaging support this mimic.

03

Muscle tear or haematoma

A clear exertional injury, focal muscle tenderness, bruising or anticoagulant-associated bleeding favours soft-tissue damage. Ultrasound can identify a collection while assessing venous compressibility.

04

Superficial vein thrombosis

A palpable tender cord with local erythema follows a superficial vein rather than causing diffuse deep swelling. Proximity to the deep system determines whether further imaging is needed.

05

Lymphoedema or chronic venous disease

Longstanding swelling, skin thickening, gaiter pigmentation or established varices favour a chronic process. Abrupt asymmetry or deep pain still requires exclusion of superimposed DVT.

Management

01likelyWells score at least 2First stepClinically suspected DVT with a likely 2-level Wells score.+
  1. 1First: proximal leg-vein ultrasound with result within 4 hours if possible.
  2. 2Next: if ultrasound cannot be obtained within 4 hours, take D-dimer, give interim therapeutic anticoagulation and obtain ultrasound within 24 hours.
  3. 3Next: if scan is positive, continue treatment; if negative, use D-dimer to decide discharge versus repeat scan.
  4. 4EscalationEscalation: after a negative scan with a positive D-dimer, stop interim therapeutic anticoagulation unless it is treating another indication, and repeat proximal ultrasound in 6–8 days; give clear PE and deterioration safety-netting.
02unlikelyWells score 1 or lessClinically suspected DVT with an unlikely 2-level Wells score.+

Complications

01

Pulmonary embolism

A detached thrombus can obstruct pulmonary arteries, causing pleuritic pain, dyspnoea, hypoxaemia, syncope or shock. Proximal DVT generally carries a higher risk of clinically important embolisation than isolated distal disease.

02

Post-thrombotic syndrome

Residual obstruction and valve damage create chronic venous hypertension. Persistent pain, heaviness, oedema, pigmentation and ulceration may substantially impair mobility and quality of life.

03

Phlegmasia and venous gangrene

Extensive iliofemoral occlusion can cause massive swelling, cyanosis and severely reduced microvascular perfusion. Sensory or motor change indicates threatened limb viability and demands emergency specialist assessment.

04

Recurrent venous thromboembolism

Persistent provoking factors, cancer, thrombophilia or an unprovoked first event can lead to recurrent DVT or PE. Recurrence risk influences the duration of anticoagulation.

05

Chronic thromboembolic pulmonary disease

Incompletely resolved or recurrent pulmonary emboli may organise within pulmonary arteries, causing persistent breathlessness, pulmonary hypertension and right-heart strain in a minority of patients.

Monitoring and follow-up

  • Review baseline FBC, renal/liver function and coagulation results within 24 hours of starting interim treatment.
  • For DOACs, check adherence, bleeding, interacting medicines and renal/liver function at least annually and more often with frailty, CKD or intercurrent illness.
  • For LMWH, monitor weight-based dosing, platelets and renal function; use anti-Xa only in selected specialist contexts.
  • At 3 months, make and document the stop/continue decision using provoking factors, recurrence and bleeding risk plus patient preference.
  • Assess persistent swelling, pain, skin change and ulceration for post-thrombotic syndrome and reinforce urgent PE symptoms.

Special situations

The clock applies to D-dimer too

NICE uses a 4-hour target for both scan and D-dimer results; interim anticoagulation prevents untreated delay.

One negative scan may not finish the pathway

Negative proximal ultrasound plus positive D-dimer requires a repeat scan in 6–8 days.

Take bloods, then treat

Baseline tests should be drawn before interim anticoagulation when possible, but routine waiting for results defeats the pathway.

Provoked is a management label

Classify the provoking factor explicitly because it drives the 3-month review; minor or persistent factors may not carry the same low recurrence risk as major transient surgery.

Cancer search is targeted

For unprovoked DVT, do not add CT cancer screening without relevant symptoms or signs after history, examination and baseline tests.

Common pitfalls

  1. 01

    Ordering D-dimer in a DVT-likely patient and delaying ultrasound rather than following the NICE sequence.

  2. 02

    Stopping after one negative proximal scan despite a positive D-dimer.

  3. 03

    Giving rivaroxaban 15 mg or 20 mg without food.

  4. 04

    Using a DOAC in pregnancy or established triple-positive APS without specialist justification.

  5. 05

    Calling a DVT unprovoked without documenting recent surgery, immobility, oestrogen, pregnancy and cancer context.

Practice

Two practice questions

Your practice draft is saved in this browser.

Question 1 of 2
0 correct
CardiologyOriginal SBA

Negative scan, positive D-dimer

A patient with a likely DVT Wells score has a negative proximal ultrasound but a positive D-dimer. What should happen next?

Choose one answer, then submit
← Rapid synopsisBack to overviewAll Cardiology topics →
Sources and review status6 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE NG158: Venous thromboembolic diseases—recommendationsWells/D-dimer/ultrasound pathways, interim anticoagulation, treatment and duration.
  • NICE NG158 visual summaryTime-critical diagnostic algorithms.
  • eMC: Eliquis 5 mg SmPCApixaban DVT dosing and cautions.
  • eMC: Xarelto 20 mg SmPCRivaroxaban DVT dosing, food requirement and special populations.
  • eMC: Clexane SmPCEnoxaparin therapeutic dosing and renal adjustment.
  • eMC: Dabigatran 150 mg SmPCDVT/PE lead-in, adult dose, dose-reduction groups and renal contraindication.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom
Pregnancy test and targeted cancer assessment
Why
Identify major treatment modifiers.
Interpretation and limitations
Use LMWH-based obstetric pathways in pregnancy. For unprovoked DVT, NICE recommends history, examination and baseline bloods—not routine extensive cancer imaging without symptoms/signs.
1
First: quantitative D-dimer with result within 4 hours; consider an age-adjusted threshold over age 50.
  • 2Next: if the result is delayed beyond 4 hours, give interim therapeutic anticoagulation while awaiting it.
  • 3Next: negative D-dimer excludes DVT; positive D-dimer leads to proximal ultrasound within 4 hours if possible, otherwise interim therapy and scan within 24 hours.
  • 4EscalationEscalation: pursue another diagnosis when DVT is excluded, while safety-netting for PE or worsening symptoms.
    • 03confirmedConfirmed proximal DVTPositive proximal ultrasound or other objective confirmation.+
    1. 1First: offer apixaban or rivaroxaban when suitable; otherwise choose LMWH followed by dabigatran/edoxaban or LMWH plus VKA according to NICE modifiers.
    2. 2Next: treat for at least 3 months and address provoking factors, mobilisation, analgesia and PE warnings.
    3. 3Next: at 3 months reassess provoked/unprovoked status, recurrence risk, bleeding, preference, renal/liver function and cancer status.
    4. 4EscalationEscalation: seek specialist advice for pregnancy, triple-positive APS, severe renal/hepatic impairment, active cancer, extremes of body weight, recurrence on therapy or phlegmasia.
    04special groupsChoice modifiersA condition that makes routine DOAC treatment uncertain or unsuitable.+
    1. 1First: pregnancy/breastfeeding—use an obstetric/haematology LMWH pathway, not a DOAC.
    2. 2Next: established triple-positive APS—offer LMWH or UFH concurrently with a vitamin K antagonist for at least 5 days or until INR is at least 2.0 in 2 consecutive readings, then continue VKA alone.
    3. 3Next: renal/hepatic impairment, active cancer or weight below 50 kg/above 120 kg—select and monitor therapy with specialist/product guidance.
    4. 4EscalationEscalation: major bleeding, recurrent VTE or suspected HIT needs immediate anticoagulation review and specialist management.
    Key medicines and prescribing safety4 treatments · regimens, roles and cautions+
    First-line NICE option for confirmed proximal DVT/PE when suitable.

    Apixaban

    10 mg orally twice daily for 7 days, then 5 mg twice daily; if extended prevention is chosen after 6 months, 2.5 mg twice daily.

    Check renal/hepatic function, interactions and bleeding; use caution with creatinine clearance 15–29 mL/min. Contraindicated in active significant bleeding and not used for pregnancy/breastfeeding.

    First-line NICE option for confirmed proximal DVT/PE when suitable.

    Rivaroxaban

    15 mg orally twice daily with food for 21 days, then 20 mg once daily with food; after at least 6 months, 10 mg once daily (or 20 mg once daily if recurrence risk is high).

    Check renal/hepatic function, interactions and bleeding. The 15 mg and 20 mg doses must be taken with food; contraindicated in pregnancy/breastfeeding.

    Therapeutic LMWH for interim treatment and when LMWH is preferred, including pregnancy pathways.

    Enoxaparin

    1 mg/kg subcutaneously every 12 hours (or 1.5 mg/kg once daily in selected uncomplicated patients); if creatinine clearance is 15–30 mL/min, use 1 mg/kg once daily.

    Dose by actual weight. Enoxaparin is not recommended when creatinine clearance is below 15 mL/min outside prevention of thrombus in the extracorporeal dialysis circuit. Monitor platelets/bleeding and consider anti-Xa in selected pregnancy, extremes of weight or renal impairment. Avoid with previous HIT.

    NICE alternative after initial LMWH when apixaban/rivaroxaban are unsuitable.

    Dabigatran

    150 mg orally twice daily after at least 5 days of therapeutic parenteral anticoagulation. Use 110 mg twice daily at age 80 years or older or with concomitant verapamil; consider 110 mg twice daily at age 75–79, CrCl 30–50 mL/min, gastritis/oesophagitis/reflux or other increased bleeding risk.

    The lower DVT/PE dose is based on pharmacokinetic/pharmacodynamic analyses rather than study in this clinical setting. Contraindicated if CrCl <30 mL/min; review P-glycoprotein interactions and bleeding. Capsules must be swallowed whole.